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ABSTRACT 
Various substituted chalcone derivatives (4A-4E) were synthesized. The structures of these compounds were established by spectral 
(IR, 1H-NMR, Mass) analysis. The synthesized compounds were screened for their antihyperglycemic activity. Compound 4-C (2-(3-
(4-methoxyphenyl)-1H-pyrazol-5-yl) phenol) was found to possess potent antihyperglycemic activity. 
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INTRODUCTION:  
Diabetes mellitus (DM) is a heterogeneous metabolic 
disorder that is characterized by high levels of blood 
glucose with disturbances of carbohydrate, lipid, and 
protein metabolism resulting from defects in insulin 
secretion, insulin action, or both. Various heterocyclic 
derivatives of substituted chalcone compounds possess  
différent biological activities such as Protein Tyrosine 
Phosphatases (PTP)-1B inhibitory, antifungal, anti-
inflammatory, anticonvulsant, antitubercular and 
immunomodulatory activity. The deregulation of PTP 
activity contributes to the pathogenesis of several human 
diseases, including cancer, diabetes, and immune 
disorders
1–3
. PTP1B plays an important role in down-
regulating insulin signaling cascades via tyrosine 
dephosphorylation of the insulin receptor, which renders 
it inactive, or dephosphorylation of insulin receptor 
substrates 1 and 2, which inhibits their interactions with 
downstream signaling molecules (Figure 1) 
2-4
. The 
present investigation involves docking, synthesis and 
evaluation of novel derivatives of substituted chalcone 
via cyclization of substituted chalcone and their 
screening for antihyperglycemic activity.  
 
 
Figure 1: Role of PTP1B in hyperglycemia. 
MATERIALS AND METHODS: 
Melting points were determined on a capillary melting 
point apparatus (Lab Hosp). IR spectra were determined 
with a Thermo-Electron FT-IR spectrophotometer 
within range 400-4000 cm
-1
. 
1
H NMR spectra were 
recorded on a Bruker’s AVANCE-III 400MHz FT NMR 
spectrometers. The mass spectra were measured on a 
Bruker microTOF QII mass spectrometer coupled to 
waters acquity LC system.  
General Procedure for Synthesis of Substituted 
Chalcones: 3 (A-E)  
A solution of sodium hydroxide (30%) in water and 
rectified spirit (100 mL) was continuously stirred in 
mechanical stirrer under ice cooled condition. 
Substituted acetophenone (0.015 mol) followed by 
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substituted benzaldehydes (0.025 mol) was continuously 
added. The mixture stirred until it became thick enough 
(Approx. 6 hr). The reaction mixture was kept at 8
o
C 
overnight. The product was filtered and recrystallized 
from ethanol. 
General Procedure for Synthesis of Heterocyclic 
Derivatives of Substituted Chalcones: 4 (A-E)  
A mixture of substituted Chalcones 4 (A-E) (0.01 mol) 
and hydroxylamine hydrochloride (0.02 mol) in ethanol 
(50 mL) was refluxed for 6 hrs on a water bath followed 
with addition of ice cold water at room temperature. The 
mixture was kept overnight at 8
o
C. The precipitates 
were filtered, washed with distilled water and dried. The 
product was recrystallized with ethanol to obtain the 
final product 4 (A-E). 
 
 
Scheme 1: Synthesis of proposed compounds. 
 
Table 1: Details of synthesized compounds 
S. No. Compound code R1 R2 
1.  4A  4-OH  4-OMe  
2.  4B  3-OH  4-OMe  
3.  4C  2-OH  4-OMe  
4.  4D  4-OH  3,4-Dimethoxy  
5.  4E  4-OH  3,4-Methylenedioxy  
 
Table 2: Spectral analysis of the synthesized compounds 
Compound 
code 
Mol. formula 
Mol. 
weight 
M.P. 
(ºC)* 
IR spectra 
(cm
-1
) 
Mass 
Spectra 
(Molecular 
ion peak) 
1
H NMR Spectra 
(δ) in ppm 
4 A C16H14N2O2 266.29 
170-
175ºC 
3246 (O-H str.), 3236 
(aromatic N-H str.), 3229 
(C-H str.), 3022 (C-H str. 
aliphatic), 1522 (C=C 
str.), 1420 (C=N str. 
aromatic), 820 (C-H bend, 
aromatic). 
268 
7.5 (r, 4H, aromatic 
ring), 6.7-7.37 (m, 
4CH, aromatic 
ring), 5.0 (d, COH    
aromatic), 2.87-3.7 
(s, OCH3), 13.7 (r, 
NH). 
4 B C16H14N2O2 266.29 
160-
165ºC 
3246 (O-H str.), 3236 
(aromatic N-H str.), 3229 
(C-H str.), 3025 (C-H str. 
aliphatic), 1690 (C=C 
str.), 1425 (C=N str. 
aromatic), 901 (C-H   
bend). 
268 
7.6 (r, 4H, aromatic 
ring), 6.8-7.37 (m, 
4CH, aromatic 
ring), 5.0 (d, COH 
aromatic), 2.87-3.7 
(s, OCH3), 13.7 (r, 
NH). 
4 C C16H14N2O2 266.29 
161-
166ºC 
3246 (O-H str.), 3236 
(aromatic N-H str.), 3229 
(C-H str.), 3025 (C-H str. 
aromatic), 1416 (C=N str. 
267.80 
7.6 (r, 4H, aromatic 
ring), 6.79-7.37(m, 
4CH, aromatic 
ring), 5.0(d, COH 
R1
CH3
O
+
OHC
R2
O
R2R1
I
Substituted Chalcone
3 (A-E)
NHN
R2
4 (A-E)
NH2NH2.H2O/  
C2H5OH
CHALCONE
Substituted Benzophenone
1 (A-C)
Substituted benzaldehyde
2 (A-C)
R1
Jain et al                                                                                                             Journal of Drug Delivery & Therapeutics. 2017; 7(7):154-157                       
ISSN: 2250-1177                                                                             [156]                                                                             CODEN (USA): JDDTAO 
aromatic), 1352 (C=C 
str.), 910 (C-H bend). 
aromatic), 2.87- 
3.7(s, OCH3), 13.7 
(r, NH). 
4 D C17H16N2O3 296.32 
180-
185ºC 
3082 (O-H str.), 3232 
(aromatic C-H str.), 1609 
(N-H bend), 1520 (C=C 
str.), 1120 (C-O-C str. 
asymmetric), 910 (C-H 
bend), 876 (C-H bend). 
 
294.12 
7.6 (r, 4H, aromatic 
ring), 6.79-7.31 (m, 
4CH, aromatic 
ring), 5.0(d, COH 
aromatic), 2.87-3.7 
(s, 2OCH3), 13.7 
(r, NH). 
4 E C16H12N2O3 280.28 
166-
171ºC 
3082 (O-H str.), 3232 
(aromatic C-H str.), 
1609(N-H bend), 1520 
(C=C str.), 1495 (C-O-C 
str. asymmetric), 947(C-H 
bend), 875 (C-H bend). 
282.11 
7.6 (r, 4H, aromatic 
ring), 6.79-7.31 (m, 
4CH, aromatic 
ring), 5.0 (d, COH 
aromatic), 5.9 (d, 
CH2 in ring), 13.7 
(r, NH). 
*uncorrected 
Biological Activity:  
All the synthesized compounds 4 (A-E) were screened 
for their antihyperglycemic activities by Sucrose Loaded 
Diabetic model using albino mice. Fasting blood glucose 
level of each animal was checked by glucometer using 
glucostrips (ACCU-CHEK) after 16 h starvation. 
Animals showing blood glucose level between 60 to 80 
mg/dl at 0 min were finally selected and divided into 
groups of five animals in each. Mice of experimental 
group were administered the suspension of the test 
sample orally prepared in 0.1 % CMC at desired dose 
levels i.e. 100 mg/kg body weight of compounds and 
standard antidiabetic drug i.e. glibenclamide. Animals of 
control group were given an equal amount of 0.1 % 
CMC. An oral sucrose load of 10 g/kg body weight was 
always given to each animal exactly after 30 min post 
administration of the test sample/ vehicle. Blood glucose 
profile of each mice was again determined at 30, 60, 90 
and 120 min post administration of sucrose.  
 
 
Figure 2: Flow chart for antihyperglycemic activity using “Sucrose Loaded Diabetic Model” 
Molecular docking 
The protein structure (PDB ID: 2QBP) downloaded 
from protein data bank was used without any 
modification. In view of biological activity of pyrrazoles 
the potential of some substituted Pyrrazoles for PTP-1B 
inhibition was studied using molecular docking. Some 
of the designed compounds were docked in the active 
site of PTP-1B using Python prescription (PyRx). 
Among these compounds 4-C (2-(3-(4-methoxyphenyl)-
1H-pyrazol-5-yl) phenol) was found to have decent 
binding free energy (-8.4 KJ/Mol), thus this compound 
can be considered as a hit for development of PTP-1B 
inhibitors. 
 
Figure 3: PTB 1B binding sites. 
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RESULTS AND DISCUSSION: 
The synthesis of substituted chalcone derivatives 4(A-E) 
is outlined in Scheme 1. All the synthesized substituted 
chalcone derivatives 4(A-E) was characterized by 1H 
NMR, IR and Mass spectral data. In general the IR 
spectral data of all the substituted chalcone derivatives 
4(A-E) indicated the presence of distinctive functional 
groups. The mass spectra of compounds showed (M+1) 
peaks, is in agreement with their molecular formula. The 
1H NMR data for the chalcone derivatives 4(A-E) were 
also is in agreement with the assigned structures. All the 
compounds were evaluated for antihyperglycemic 
activity by observing their fall in blood glucose level 
towards sucrose loaded diabetic model. Pharmacological 
data of the compounds have been given in table. 
Docking scores predict that all the synthesized 
compounds 4(A-E) will show slight difference in 
activity with 4C having highest activity. These docking 
results are in accordance with the results of in vivo 
activity.
 
Table 3: Result of in vivo Antihyperglycemic activity of synthesized derivatives 
S. No. Compounds Percentage Antihyperglycemic  Activity  
1. 4-A 32.5 
2. 4-B 34.0 
3 4-C* 70.0 
4. 4-D 49.2 
5. 4-E 34.8 
6. Glibenclamide (Standard) 68.0 
Data presented as % anti-hyperglycemic effect on comparison with standard group. 
*indicates most potent compound. 
CONCLUSION: 
From the results of in-vivo antihyperglycemic activity, it 
is concluded that these molecules can be designed as a 
potential drugs. Among all the synthesized compound 4-
C exhibited remarkable anti hyperglycemic effect which 
are also, supported by docking study. Therefore results 
of study suggested that the heterocyclic derivatives of 
substituted chalcone may be exploited as commercial 
anti hyperglycemic agents. 
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